Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on August 6, 2015. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The document primarily functions as a cover sheet to submit a news release regarding the company's scheduled presentation at the Canaccord Genuity 35th Annual Growth Conference.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing referencing an external news release and does not contain a financial statement or performance data within the provided text.
Material Changes
No material changes to financial performance or operations are detailed in this specific filing text. The content is limited to the announcement of an upcoming investor conference presentation.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, risk factors, or contingencies. The sole substantive item is the disclosure that the company will present at the Canaccord Genuity 35th Annual Growth Conference.
Key Facts for Investor Verification
- The filing is a Form 6-K dated August 6, 2015, signed by Michael R. Martin, Chief Operating Officer.
- The primary purpose is to distribute a news release (Exhibit 99.1) regarding a conference presentation.
- No financial data is included in this specific document; investors must refer to the referenced news release or other periodic reports for financial metrics.
- The company is a foreign private issuer filing under Form 40-F.